
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Ventyx Biosciences Inc (VTYX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VTYX (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $11.5
1 Year Target Price $11.5
5 | Strong Buy |
1 | Buy |
3 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.36% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 213.93M USD | Price to earnings Ratio - | 1Y Target Price 11.5 |
Price to earnings Ratio - | 1Y Target Price 11.5 | ||
Volume (30-day avg) 9 | Beta 0.97 | 52 Weeks Range 0.78 - 3.39 | Updated Date 08/15/2025 |
52 Weeks Range 0.78 - 3.39 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.66 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.46 | Actual -0.38 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.23% | Return on Equity (TTM) -48.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 15261554 | Price to Sales(TTM) - |
Enterprise Value 15261554 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -22.93 | Shares Outstanding 71308496 | Shares Floating 55662716 |
Shares Outstanding 71308496 | Shares Floating 55662716 | ||
Percent Insiders 4.11 | Percent Institutions 67.33 |
Upturn AI SWOT
Ventyx Biosciences Inc
Company Overview
History and Background
Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines for autoimmune and inflammatory diseases. It was founded in 2020. The company's strategy involves acquiring or in-licensing promising drug candidates and advancing them through clinical development.
Core Business Areas
- Drug Development: Focuses on the development of oral, small molecule therapies targeting validated biological pathways for autoimmune and inflammatory diseases.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. Specific leadership details would require real-time search as personnel changes are common. The structure is typical for a biotech company, with research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- Vtx-958: A selective allosteric TYK2 inhibitor being developed for psoriasis, psoriatic arthritis, and Crohn's disease. Clinical trials are ongoing. Competitors include BMS's Sotyktu and other TYK2 inhibitors in development. Market share is currently zero due to being in clinical trials, but represents an entry into a large and growing market.
- Vtx-801: An NLRP3 inhibitor being developed for various inflammatory conditions. Clinical trials are ongoing. Competitors include other companies developing NLRP3 inhibitors, such as Olatec Therapeutics. Market share is currently zero due to being in clinical trials, but represents an entry into a large and growing market.
- Vtx-3232: A peripheral S1P1 receptor modulator in development for autoimmune diseases. Clinical trials are ongoing. Competitors include other S1P modulators like ozanimod (Zeposia) from BMS. Market share is currently zero due to being in clinical trials, but represents an entry into a large and growing market.
Market Dynamics
Industry Overview
The biopharmaceutical industry for autoimmune and inflammatory diseases is large and competitive, driven by high unmet medical needs and increasing prevalence of these conditions.
Positioning
Ventyx aims to differentiate itself by developing oral, small molecule therapies with improved efficacy and safety profiles compared to existing treatments. Their competitive advantage lies in their targeted approach to validated biological pathways.
Total Addressable Market (TAM)
The TAM for autoimmune and inflammatory disease treatments is estimated to be over $100 billion globally. Ventyx is positioned to capture a portion of this market with its pipeline of drug candidates. The precise addressable market for each product is dependent on the specific indications they are targeting.
Upturn SWOT Analysis
Strengths
- Promising drug pipeline targeting validated pathways
- Experienced management team
- Oral, small molecule approach offers convenience
- Strong intellectual property portfolio
Weaknesses
- Clinical trial risk
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Limited commercial infrastructure
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Potential for breakthrough therapies
Threats
- Competition from established players
- Regulatory hurdles
- Patent challenges
- Unfavorable clinical trial data
Competitors and Market Share
Key Competitors
- BMY
- PFE
- ABBV
Competitive Landscape
Ventyx faces competition from established pharmaceutical companies with marketed products and other biotech companies developing similar therapies. Ventyx's success depends on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of the drug pipeline and advancement through clinical trials.
Future Projections: Future growth is contingent on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates vary depending on perceived probabilities of success.
Recent Initiatives: Recent initiatives include progressing lead drug candidates through clinical trials, initiating new clinical studies, and potential strategic collaborations.
Summary
Ventyx Biosciences is a clinical-stage biopharmaceutical company with a focus on autoimmune and inflammatory diseases. The company's strength lies in its promising drug pipeline and experienced management team. However, it faces risks associated with clinical trial outcomes and competition from established players. Successful clinical trials and potential partnerships will be crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on available data and is subject to change. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ventyx Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-10-21 | Founder, CEO, President & Director Dr. Raju S. Mohan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://ventyxbio.com |
Full time employees 81 | Website https://ventyxbio.com |
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.